pancreatic cancer clinical trials

Pancreatic Cancer - Clinical Trials

Rank NCT ID Title Recruitment Interventions Sponsors PhasesEnrollmen

tStudy Designs

First Received

Start DateCompletion

DateLast

UpdatedLast

Verified

Primary Completion

Date

233 NCT00274885

Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer

RecruitingDrug: oxaliplatin|Procedure: management of therapy

complications

Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)

Phase IV 58

Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment

10-Jan-06 Oct-05 6-Feb-09 May-07

7 NCT00003029

Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

Active, not recruiting

Drug: cisplatin|Drug: fluorouracil

European Organization for Research and

Treatment of Cancer

Phase III 200

Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment

1-Nov-99 May-97 23-Jul-08 Oct-02

32 NCT00003049

Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas


Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation:

radiation therapy

Mayo Clinic|National Cancer Institute

(NCI)Phase III 100


1-Nov-99 May-97 6-Feb-09 Sep-03

46 NCT00003170Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer


Dietary Supplement: glutamine

North Central Cancer Treatment

Group|National Cancer Institute

(NCI)

Phase III 120

Allocation: Randomized|Primary Purpose: Supportive

Care

1-Nov-99 Feb-98 6-Feb-09 May-07

11 NCT00003216

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Completed

Drug: fluorouracil|Drug: gemcitabine

hydrochloride|Radiation: radiation therapy

Radiation Therapy Oncology

Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology

Group|Southwest Oncology Group

Phase III 518


1-Nov-99 Jul-98 28-Mar-09 Apr-03 Mar-08

19 NCT00005648

Gemcitabine With or Without R115777 in Treating Patients With Advanced Pancreatic Cancer


Drug: gemcitabine hydrochloride|Drug: tipifarnib

Janssen Pharmaceuticals

Phase IIIAllocation:

Randomized|Primary Purpose: Treatment

2-May-00 Nov-99 23-Jul-08 Jun-07

21 NCT00005869

Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer


Drug: gemcitabine hydrochloride|Drug: rubitecan

SuperGen Phase IIIAllocation:


2-Jun-00 Nov-98 23-Jul-08 Jun-07

25 NCT00005871

Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer


Drug: fluorouracil|Drug: rubitecan



2-Jun-00 Nov-98 23-Jul-08 Jun-07

1 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

26 NCT00005870

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas


Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: mitomycin C|Drug: rubitecan



2-Jun-00 Mar-99 23-Jul-08 Jun-07

39 NCT00014651

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection


Drug: vapreotide|Procedure: conventional surgery


(NCI)Phase III

Primary Purpose: Supportive Care

10-Apr-01 Mar-01 9-May-09 Aug-06

44 NCT00016380

Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen

CompletedDrug: dexamethasone|Drug:

ondansetron|Procedure: quality-of-life assessment

NCIC Clinical Trials Group

Phase III

Allocation: Randomized|Control:

Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive

Care

6-May-01 Feb-01 Feb-09 5-Mar-10 Mar-10

22 NCT00024427

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer


Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug:

triacetyluridineWellstat Therapeutics Phase III

Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment

13-Sep-01 Feb-01 9-May-09 May-05

13 NCT00023972

Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer


Drug: exatecan mesylate|Drug: gemcitabine hydrochloride

Daiichi Sankyo Inc. Phase III


13-Sep-01 Jul-01 23-Jul-08 Nov-02

28 NCT00026338

Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

CompletedDrug: erlotinib

hydrochloride|Drug: gemcitabine hydrochloride


Phase IIIPrimary Purpose:

Treatment9-Nov-01 Aug-01 Feb-09 5-Mar-10 Mar-10

1 NCT00030732

Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer


Drug: capecitabine|Drug: gemcitabine hydrochloride

Swiss Group for Clinical Cancer Research|Central

European Cooperative

Oncology Group

Phase III


14-Feb-02 Jun-01 13-Aug-08 Aug-08

18 NCT00032175

Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

CompletedDrug: capecitabine|Drug: gemcitabine hydrochloride

Cancer Research UK Phase III 508


8-Mar-02 Apr-02 13-Jan-10 Apr-07

30 NCT00031837

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed

Drug: dalteparin|Drug: gemcitabine

hydrochloride|Procedure: quality-of-life assessment

University of Rochester|National Cancer Institute

(NCI)

Phase III 400


8-Mar-02 Oct-02 19-Aug-09 Jan-072 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

6 NCT00033735

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer


Drug: fluorouracil|Drug: irofulven

Eisai Inc. Phase IIIPrimary Purpose:

Treatment9-Apr-02 Jan-00 23-Jul-08 Jun-02

52 NCT00035035

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Completed Drug: GEMZAR|Drug: ALIMTA Eli Lilly and Company Phase III

Allocation: Randomized|Control: Active Control|Endpoint

Classification: Safety/Efficacy

Study|Intervention Model: Parallel

Assignment|Masking: Open Label|Primary Purpose: Treatment

2-May-02 18-Jul-06 Jul-06

63 NCT00040092

A Study to Test the Effectiveness of VirulizinÂ® Given in Combination With Standard Chemotherapy for Pancreatic Cancer

Completed Drug: VirulizinÂ® Lorus Therapeutics Phase III 400

Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel

Assignment|Masking: Double-Blind|Primary Purpose: Treatment

19-Jun-02 Jul-02 4-Jan-08 Jan-08 Jul-05

71 NCT00040183

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

CompletedDrug: Tarceva (erlotinib HCl,

OSI-774)

OSI Pharmaceuticals|NCIC Clinical Trials

Group

Phase III 500


Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel


21-Jun-02 Oct-01 Sep-04 25-Jan-06 Jan-06

85 NCT00044031

Safety and Efficacy of G17DT Immunogen in the Treatment of Advanced Pancreatic Carcinoma


Drug: G17DT Immunogen Aphton Phase III


Placebo Control|Endpoint Classification: Safety/Efficacy



16-Aug-02 Feb-01 23-Jun-05 Mar-03

3 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

2 NCT00049426

Gemcitabine With or Without Pemetrexed Disodium in Treating Patients With Unresectable Stage II, Stage III, or Stage IV Pancreatic Cancer


Dietary Supplement: cyanocobalamin|Dietary

Supplement: folic acid|Drug: gemcitabine hydrochloride|Drug:

pemetrexed disodium

Ireland Cancer Center|National Cancer Institute

(NCI)

Phase III


12-Nov-02 Jul-02 6-Feb-09 Mar-03

56 NCT00051467

A Study of TNFeradeâ„¢ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer


Genetic: TNFerade GenVec Phase III

Allocation: Randomized|Endpoint


Study|Masking: Open Label|Primary Purpose:

Treatment

10-Jan-03 31-Mar-10 Mar-10

23 NCT00058201

Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer



leucovorin calcium|Other: clinical observation

Royal Liverpool University

Hospital|NCIC Clinical Trials

Group|Australasian Gastro-Intestinal Trials Group

Phase III 1030


7-Apr-03 Jul-01 13-Dec-09 May-08 Apr-08

24 NCT00058149

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

CompletedDrug: gemcitabine

hydrochloride|Drug: oxaliplatin

Eastern Cooperative Oncology


(NCI)

Phase III


7-Apr-03 Mar-03 11-Jul-09 Apr-04 Jul-06

9 NCT00057876

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer




Group|National Cancer Institute (NCI)|Radiation Therapy Oncology

Group

Phase III


7-Apr-03 Apr-03 29-May-09 Jan-06 May-09

31 NCT00075452

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma


Drug: gemcitabine hydrochloride|Drug: oxaliplatin


Phase III


9-Jan-04 Nov-03 23-Jul-08 May-07

16 NCT00075686

Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas


Biological: cetuximab|Drug: gemcitabine hydrochloride

Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group

B|NCIC Clinical Trials Group

Phase III


9-Jan-04 Jan-04 6-Feb-09 Aug-06

4 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

105 NCT00079833

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

Completed Drug: Esomeprazole magnesium AstraZeneca Phase III 25

Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

16-Mar-04 Jul-03 Jul-05 25-Mar-09 Mar-09

54 NCT00088660

PANVACâ„¢-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen


Biological: PANVACâ„¢-VFTherion Biologics Corporation

Phase III 250



Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

30-Jul-04 Jun-04 7-Feb-06 Feb-06

5 NCT00088894

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer


Biological: bevacizumab|Drug: gemcitabine hydrochloride

Cancer and Leukemia Group B|National Cancer Institute

(NCI)

Phase III


Placebo Control|Masking: Double-Blind|Primary Purpose: Treatment

4-Aug-04 Jun-04 25-Jul-09 Apr-06

33 NCT00099294

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Completed Drug: GlufosfamideThreshold

Pharmaceuticals|PPDPhase III 300

Allocation: Randomized|Control: Uncontrolled|Endpoint




10-Dec-04 Sep-04 Jan-07 28-Apr-09 Apr-09 Jan-07

206 NCT00132704

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation


Radiation: Ionizing radiation (IR) therapy|Radiation: Ionizing

radiation (IR)

Memorial Sloan-Kettering Cancer Center|National Cancer Institute

(NCI)

Phase III 149Observational Model:

Cohort|Time Perspective: Prospective

18-Aug-05 Aug-04 Aug-10 14-Aug-09 Aug-09 Aug-10

10 NCT00136669Acupuncture For Pancreatic Cancer Pain

Completed Procedure: AcupunctureMemorial Sloan-Kettering Cancer

CenterPhase III 60



Assignment|Masking: Single Blind|Primary Purpose: Treatment

25-Aug-05 Sep-03 Sep-05 7-Sep-06 Sep-06

5 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

255 NCT00200148

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy


Procedure: Normovolemic Hemodilution (ANH)|Procedure:

Standard of care

Memorial Sloan-Kettering Cancer

CenterPhase III 372

Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel

Assignment|Masking: Single Blind

(Subject)|Primary Purpose: Treatment

12-Sep-05 Mar-04 Mar-10 21-Oct-09 Oct-09 Mar-10

40 NCT00268411

Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer




Phase III 80Allocation:


20-Dec-05 Sep-04 23-May-08 May-07

51 NCT00279292Randomized Trial of EUS Neurolysis in Pancreas Cancer

CompletedProcedure: Celiac Plexus

Neurolysis

National Institute of Diabetes and

Digestive and Kidney Diseases (NIDDK)

Phase III 26


Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment

17-Jan-06 Aug-04 17-Mar-10 Mar-10

41 NCT00303758

Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed

Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin

calcium

Fondation Francaise de Cancerologie

DigestivePhase III 202

Allocation: Randomized|Primary Purpose: Treatment

15-Mar-06 Oct-05 21-Nov-09 Dec-06

58 NCT00312013

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Completed Drug: Nadroparin GlaxoSmithKline Phase III 503





5-Apr-06 May-06 Jul-09 15-Apr-10 Apr-10 Jul-09

14 NCT00358566

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

TerminatedBiological: GV1001|Drug:

Gemcitabine (Chemotherapy)

Pharmexa A/S|ICON Clinical

Research|ORION Clinical

Services|CIRION Central

Laboratory|Dorevitch|Kendle International

Phase III 360



14-Jul-06 Jun-06 Aug-08 16-May-08 May-08 Aug-08

6 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

59 NCT00353496

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

RecruitingDrug: lanreotide (Autogel formulation)|Other: Placebo

Ipsen Phase III 200



Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment

17-Jul-06 Jun-06 Jun-12 8-Mar-10 Mar-10 Jun-12

45 NCT00365508

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

Completed Drug: nicotine

Fox Chase Cancer Center|National Cancer Institute

(NCI)


Randomized|Masking: Open Label

16-Aug-06 Feb-06 5-Nov-09 Nov-09 Aug-09

279 NCT00401076

A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency


Drug: SA-001Solvay

Pharmaceuticals, Inc.Phase III 80

Control: Uncontrolled|Endpoint



16-Nov-06 Jan-08 Nov-10 1-Apr-10 Apr-10 Nov-10

38 NCT00416507

Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery


Drug: cisplatin liposomal|Drug: fluorouracil|Drug: gemcitabine

hydrochloride

Federation Francophone de Cancerologie Digestive



27-Dec-06 23-Jul-08 May-08

72 NCT00417209

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

CompletedDrug: larotaxel

(XRP9881)|Drug: 5-FluorouracilSanofi-Aventis Phase III 400



28-Dec-06 Dec-06 Nov-09 18-Dec-09 Dec-09 Jul-09

17 NCT00425360

Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Recruiting

Biological: sargramostim|Biological: telomerase peptide vaccine

GV1001|Drug: capecitabine|Drug: gemcitabine

hydrochloride

Royal Liverpool University Hospital

Phase III 1110


19-Jan-07 Sep-06 23-Dec-09 May-09

7 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

125 NCT00428220

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.


Drug: sunitinib Pfizer Phase III 300

Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

26-Jan-07 Jul-07 May-14 6-Apr-10 Apr-10 May-14

80 NCT00428597

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

TerminatedDrug: sunitinib malate|Drug:

PlaceboPfizer Phase III 171





29-Jan-07 Mar-07 Apr-09 14-Jul-09 Jul-09 Apr-09

15 NCT00440167

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotnib Followed of Capecitabine


Drug: gemcitabine|Drug: capecitabine|Drug: Erlotinib

Ludwig-Maximilians - University of Munich|Roche Pharma AG

Phase III

Allocation: Randomized|Control: Uncontrolled|Endpoint


Study|Intervention Model: Crossover


22-Feb-07 Jun-06 22-Oct-09 Oct-09

29 NCT00471146

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.


Drug: AG-013736|Drug: Gemcitabine|Drug:

Gemcitabine|Drug: placeboPfizer Phase III 632





7-May-07 Aug-07 Sep-10 2-Apr-10 Apr-10 Jan-09

37 NCT00477919

Electronic Tool to Record Cancer Symptoms in Patients With Advanced Cancer Receiving Palliative Care

Recruiting

Other: counseling intervention|Procedure:

cognitive assessment|Procedure: fatigue assessment and management|Procedure:

psychosocial assessment and care|Procedure: quality-of-life

assessment

Swiss Group for Clinical Cancer Research

Phase III 192

Allocation: Randomized|Control: Active Control|Primary Purpose: Health Services

Research

23-May-07 Feb-07 30-Oct-09 Jul-09 Jun-10

8 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

4 NCT00486460

Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer

RecruitingDrug: Gemcitabine|Drug: Curcumin|Drug: Celebrex

Tel-Aviv Sourasky Medical Center

Phase III


Placebo Control|Intervention Model: Parallel

Assignment|Masking: Double-Blind

13-Jun-07 Jun-05 13-Jun-07 Jun-07

34 NCT00498225

Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer


Drug: Gemcitabine plus TS-1|Drug: TS-1|Drug: Gemcitabine

Taiho Pharmaceutical Co., Ltd.|TTY Biopharm

Phase III 750





6-Jul-07 Jul-07 Jun-13 28-Jan-10 Jan-10 Jun-12

73 NCT00510068

Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors


Drug: RAD001 (Everolimus)Novartis

PharmaceuticalsPhase III 410

Allocation: Randomized|Intervention

Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator,

Outcomes Assessor)|Primary Purpose: Treatment

31-Jul-07 Jul-07 18-Nov-09 Nov-09 Dec-10

47 NCT00538850Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

RecruitingDrug: fentanyl sublingual spray|Other: questionnaire

administration

Insys Therapeutics Inc

Phase III 130


Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive

Care

1-Oct-07 Oct-07 9-Apr-10 Oct-08 Dec-08

27 NCT00541021

Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

RecruitingDrug: gemcitabine

hydrochloride|Drug: sorafenib tosylate

Institut Paoli-Calmettes

Phase III 104


Placebo Control|Masking: Double-Blind|Primary Purpose: Treatment

5-Oct-07 Dec-06 13-Dec-09 Jul-09 Dec-10

292 NCT00550108Management of Incidentally Discovered Pancreatic Cysts

Terminated Other: Ethanol lavageMassachusetts General Hospital

Phase III 0





24-Oct-07 Oct-07 Oct-12 23-Jun-08 Jun-08 Oct-12

9 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

69 NCT00574275

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer


Drug: placebo|Drug: Aflibercept (AVE0005)

Sanofi-Aventis|Regeneron Pharmaceuticals

Phase III 630



Assignment|Masking: Double Blind (Subject,

Caregiver, Investigator)|Primary Purpose: Treatment

14-Dec-07 Dec-07 Nov-10 15-Sep-09 Sep-09 Nov-10

70 NCT00602745

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen


Drug: S-1|Drug: 5-FluorouracilSanofi-Aventis|Taiho Pharmaceutical Co.,

Ltd.Phase III 400



16-Jan-08 Dec-07 Jun-10 7-Apr-09 Apr-09 Jun-10

67 NCT00637728

Treatment of Cancer-Anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

TerminatedDrug: Megestrol acetate

concentrated suspension 110 mg/mL|Drug: Placebo

Par Pharmaceutical, Inc.|PRA

InternationalPhase III 5





11-Mar-08 Jun-06 Sep-06 11-Mar-08 Mar-08 Sep-06

12 NCT00634725

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Recruiting

Drug: capecitabine|Drug: erlotinib hydrochloride|Drug:

gemcitabine hydrochloride|Other: laboratory biomarker analysis|Radiation:

radiation therapy




12-Mar-08 Feb-08 2-Dec-09 Jul-09 May-11

10 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

60 NCT00644618

Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy

CompletedDrug: gemcitabine|Other: 125I brachytherapy PLUS gemcitabine

Huazhong University of Science and Technology

Phase III 120



Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

24-Mar-08 Jan-03 Jan-08 24-Mar-08 Mar-08 Dec-07

8 NCT00994721A Phase III Study of Pancreatic Cancer

Enrolling by invitation

National Health Research Institutes, Taiwan|National Taiwan University

Hospital|Chang Gung Memorial

Hospital|Taipei Veterans General

Hospital,Taiwan|Mackay Memorial

Hospital|Taichung Veterans General Hospital|National Cheng-Kung University

Hospital|Kaohsiung Veterans General Hospital.|Kaohsiung Medical University

Phase III 265Observational Model: Case Control|Time

Perspective: Prospective26-Mar-08 Feb-09 Jan-15 11-Oct-09 Oct-09 Jan-12

42 NCT00662688

Gemcitabine With or Without Capecitabine and/or Dalteparin in Treating Patients With Metastatic Pancreatic Cancer

Recruiting

Drug: capecitabine|Drug: dalteparin|Drug: gemcitabine

hydrochloride|Genetic: mutation analysis|Other: laboratory

biomarker analysis


Phase III 136

Allocation: Randomized|Control: Active Control|Primary Purpose: Supportive

Care

18-Apr-08 Oct-07 1-Dec-09 Jul-09 Jan-12

283 NCT00677677

Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients

RecruitingBiological: Human

papillomavirus quadrivalent vaccine

University of Alberta Phase III 50



Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention

12-May-08 May-08 Sep-10 11-Feb-10 Feb-10 Sep-10

11 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

75 NCT00679913Standardization of Surgery on the Pancreatic Cancer

Recruiting

Procedure: Standard pancreatoduodenectomy|Proced

ure: Extended pancreatoduodenectomy

Seoul National University Hospital

Phase III 216


Assignment|Masking: Single Blind

(Subject)|Primary Purpose: Treatment

15-May-08 Nov-05 Nov-10 17-May-08 May-08 Nov-09

35 NCT00789633

Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

RecruitingDrug: masitinib (AB1010)|Drug:

placeboAB Science Phase III 320




Assignment|Masking: Double Blind (Subject, Caregiver, Investigator,

Outcomes Assessor)|Primary Purpose: Treatment

12-Nov-08 Nov-08 Nov-11 7-Aug-09 Aug-09 Nov-10

77 NCT00806611

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

Recruiting Procedure: Alcohol BlockThomas Jefferson

UniversityPhase III 290



10-Dec-08 Sep-08 Dec-11 17-Sep-09 Sep-09 Dec-10

86 NCT00809081Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy

RecruitingProcedure: Enteral Feeding and

Total Parental SupportYonsei University Phase III 38


Uncontrolled|Intervention Model: Parallel


15-Dec-08 Jul-07 Jan-10 15-Dec-08 Dec-08 Jun-09

12 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

78 NCT00813696

Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer


Drug: gemcitabine|Drug: cisplatin

Istituti Tumori Giovanni Paolo

II|Gruppo Oncologico Italia

Meridionale(GOIM)|Gruppo Italiano per lo studio dei Carcinomi

dell'Apparato Digerente|Gruppo

Oncologico Italiano di Ricerca

Clinica|Cattedra di Endocrinochirurgia, UniversitÃ di Verona

Phase III 400



22-Dec-08 Apr-02 Sep-09 22-Dec-08 Dec-08 Mar-09

84 NCT00830778

Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy

RecruitingProcedure:

Pancreaticojejunostomy|Procedure: Pancreaticogastrostomy

University Hospital, Gasthuisberg|Erasme

ULB, Brussels|Jolimont, Brussels|St.Lucas,

Brugge|AZ.Groeninge, Kortrijk|Universite Catholique Louvain

(UCL), Brussels|St.Joseph, LiÃ¨ge|University

Hospital, Antwerp|Jan Palfijn, Antwerp|St.Jan, Brugge|Monica,

Deurne



27-Jan-09 Jun-09 Jun-12 13-Nov-09 Nov-09 Dec-11

93 NCT00842348

Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour


Drug: lanreotide Ipsen Phase III 140

Endpoint Classification: Safety


11-Feb-09 Sep-08 Dec-14 17-Feb-10 Feb-10 Dec-13

36 NCT00844649A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas

RecruitingDrug: ABI-

007/Gemcitabine|Drug: Gemcitabine

Abraxis BioScience Inc.

Phase III 630

Allocation: Randomized|Intervention

Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment

13-Feb-09 Mar-09 Jun-12 13-Apr-10 Dec-09 Dec-10

76 NCT00908960

Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

Recruiting Drug: Enoxaparin

Beth Israel Deaconess Medical Center|Massachusett

s General Hospital|North Shore

Medical Center|Sanofi-

Aventis

Phase III 227


Assignment|Masking: Open Label|Primary Purpose: Prevention

26-May-09 May-09 27-Jul-09 Jul-09 Apr-11

13 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

97 NCT00951574

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

CompletedDrug: Nadroparin calcium|Drug:

saline solution (placebo)Italfarmaco|Carlo

BianchiniPhase III 1166


Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover

Assignment|Masking: Double Blind (Subject, Caregiver, Investigator,

Outcomes Assessor)|Primary Purpose: Prevention

31-Jul-09 Oct-03 Jul-08 3-Aug-09 Aug-09 May-07

62 NCT00974948Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis

CompletedProcedure: EUS-guided celiac

plexus neurolysis

Centre hospitalier de l'UniversitÃ© de

MontrÃ©al (CHUM)Phase III 100


Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment

10-Sep-09 Apr-06 Dec-08 10-Sep-09 Sep-09 Dec-08

64 NCT00994110

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

RecruitingDrug: Pasireotide

(SOM230)|Other: placebo

Memorial Sloan-Kettering Cancer Center|Novartis Pharmaceuticals

Phase III 300





Caregiver, Investigator)|Primary Purpose: Treatment

13-Oct-09 Oct-09 Oct-11 6-Apr-10 Apr-10 Oct-11

3 NCT01013649

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By Chemotherapy With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Recruiting

Drug: capecitabine|Drug: erlotinib hydrochloride|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Radiation: 3-

dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy



(NCI)

Phase III 950

Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment

13-Nov-09 Nov-09 17-Apr-10 Apr-10 Apr-15

14 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

20 NCT01072981Vaccine Study for Surgically Resected Pancreatic Cancer

Not yet recruiting

Biological: HyperAcute-Pancreatic Cancer Vaccine

NewLink Genetics Corporation

Phase III 722





18-Feb-10 Mar-10 Jan-14 26-Feb-10 Feb-10 Jan-14

53 NCT01077427Hyperthermia European Adjuvant Trial

Not yet recruiting

Device: Gemcitabine + regional hyperthermia|Drug:

Gemcitabine

Klinikum der Universitaet Muenchen,

Grosshadern|European Society for Hyperthermic

Oncology|Institute for Medical

Informatics, Biometry and Epidemiology, Munich|ClinAssess GmbH, Leverkusen,

Germany

Phase III 366



25-Feb-10 Jan-11 Jan-16 15-Mar-10 Mar-10 Jan-16

49 NCT00064207

Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer


Drug: gemcitabine hydrochloride|Procedure:

adjuvant therapy|Radiation: radiation therapy

European Organization for Research and Treatment of

Cancer|Federation Francophone de Cancerologie Digestive

Phase II|Phase III

538


8-Jul-03 May-03 21-Nov-09 Nov-06

43 NCT00112658

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer


Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug:

oxaliplatin

Federation Nationale des Centres de Lutte Contre le Cancer

Phase II|Phase III

348


2-Jun-05 Nov-04 20-Feb-10 Dec-06

61 NCT00113256

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Completed Drug: Rubitecan SuperGenPhase II|Phase

III30

Allocation: Non-Randomized|Control: Uncontrolled|Endpoint



6-Jun-05 Feb-05 12-Oct-09 Oct-09

15 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

68 NCT00192712Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer


Drug: irinotecan, gemcitabineRambam Health Care

CampusPhase II|Phase

III20

Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

11-Sep-05 Nov-02 Feb-05 13-Dec-05 Sep-05

82 NCT00233038EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial

CompletedProcedure: Ethanol injection into

a cyst

Massachusetts General

Hospital|Indiana University School of

Medicine

Phase II|Phase III

50

Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover


3-Oct-05 Jan-05 Mar-08 25-Jun-08 Jun-08 Dec-07

81 NCT00332280

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Recruiting Drug: AMT2003Auron Healthcare

GmbHPhase II|Phase

III200




Assignment|Masking: Single Blind|Primary Purpose: Treatment

31-May-06 May-06 Dec-08 29-Nov-06 Nov-06

79 NCT00363051

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy


Drug: Everolimus NovartisPhase II|Phase

III144




2-Aug-06 Jun-06 18-Nov-09 Nov-09

55 NCT00689715

Efficacy Study of Endoscopic Ultrasonography (EUS)-Guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas

RecruitingProcedure: Endoscopic

ultrasonography-guided ethanol lavage with paclitaxel injection

Asan Medical CenterPhase II|Phase

III50




2-Jun-08 Jun-06 3-Jun-08 Jun-08 May-09

16 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

66 NCT00753441

Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head

Not yet recruiting

Procedure: Surgical bypass|Procedure: Endoscopic

stenting

University of Heidelberg

Phase II|Phase III

100



15-Sep-08 Sep-08 Sep-10 15-Sep-08 Jul-08 Sep-10

65 NCT00785421Chemotherapy With or Without Enoxaparin in Pancreatic Cancer

Completed

Drug: enoxaparin|Drug: chemotherapy with LMWH - enoxaparin|Drug: only

chemotherapy

CONKO-Studiengruppe|Sanofi-Aventis|Amgen|Eli Lilly and Company

Phase II|Phase III

540



4-Nov-08 Apr-04 Jun-09 12-Jun-09 Jun-09 Jan-09

48 NCT00960284

Gemcitabine Hydrochloride With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Pancreatic Cancer

Recruiting

Drug: capecitabine|Drug: cisplatin|Drug: epirubicin hydrochloride|Drug:

fluorouracil|Drug: gemcitabine hydrochloride

Istituto Scientifico H. San Raffaele

Phase II|Phase III

102Allocation:


14-Aug-09 Jun-03 29-Aug-09 Aug-09 Jun-09

124 NCT00002475

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Completed

Biological: allogeneic tumor cell vaccine|Biological: autologous tumor cell vaccine|Biological:

recombinant interferon alfa|Biological: recombinant interferon gamma|Biological:

sargramostim|Drug: cyclophosphamide

St. Vincent Medical Center - Los Angeles

Phase II 40Primary Purpose:

Treatment1-Nov-99 Apr-91 11-Jun-09 Nov-08 Dec-07

252 NCT00002689

Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer

Completed

Drug: dexamethasone|Drug: fluorouracil|Radiation:

brachytherapy|Radiation: phosphorus P32|Radiation:

radiation therapy

Center for Molecular Medicine


Treatment1-Nov-99 Sep-95 6-Feb-09 Jun-07

96 NCT00003018

Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

CompletedDrug: dipyridamole|Drug: fluorouracil|Drug: leucovorin calcium|Drug: mitomycin C

Southwest Oncology Group|National Cancer Institute

(NCI)


Treatment1-Nov-99 Sep-97 23-Jul-08 May-07

127 NCT00003125

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors


Biological: ALVAC-CEA vaccine|Biological:

aldesleukin|Biological: sargramostim|Biological: vaccinia-CEA vaccine

Lombardi Cancer Research

Center|National Cancer Institute

(NCI)

Phase II 24Allocation:


1-Nov-99 Jan-98 6-Feb-09 May-07

17 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

88 NCT00003434

Biological Therapy in Treating Patients With Stage I, Stage II, or Stage III Pancreatic Cancer That Has Been Surgically Removed


Biological: carcinoembryonic antigen peptide 1|Biological: hepatitis B antigen peptide

Duke University|National Cancer Institute

(NCI)


Treatment1-Nov-99 Jun-98 6-Feb-09 Jun-01

146 NCT00003546

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer


Drug: gemcitabine hydrochloride|Radiation:

radiation therapy


(NCI)


Treatment1-Nov-99 Sep-98 6-Feb-09 Aug-05

94 NCT00003760Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer


Drug: irofulvenSan Antonio Cancer

InstitutePhase II 50

Primary Purpose: Treatment

1-Nov-99 Oct-98 23-Jul-08 Jul-00

141 NCT00003591

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

CompletedDrug: paclitaxel|Radiation:

radiation therapy



(NCI)


Treatment1-Nov-99 Nov-98 6-Feb-09 Mar-08 Feb-04

221 NCT00003780

Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas


Biological: tumor infiltrating lymphocyte therapy|Drug: gemcitabine hydrochloride

Meyer Pharmaceuticals

Phase II 150Allocation:


1-Nov-99 Dec-98 6-Feb-09 May-07

91 NCT00003769

Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer

CompletedDrug: perillyl alcohol|Procedure:

surgical procedure

Indiana University School of

Medicine|National Cancer Institute

(NCI)

Phase IIPrimary Purpose:

Treatment1-Nov-99 Feb-99 17-Sep-09 Sep-09

144 NCT00003839

Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors


Biological: anti-thymocyte globulin|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug:

cyclosporine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation

National Heart, Lung, and Blood Institute

(NHLBI)Phase II 150


1-Nov-99 Mar-99 6-Feb-09 Nov-08 Dec-09

238 NCT00003923

Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas

Completed Drug: porfimer sodium


(NCI)


Treatment1-Nov-99 Mar-99 3-Dec-09 Dec-09 Feb-02

98 NCT00004003

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

CompletedDrug: cisplatin|Drug:

fluorouracil|Drug: gemcitabine hydrochloride

Barbara Ann Karmanos Cancer Institute|National Cancer Institute

(NCI)


Treatment1-Nov-99 Apr-99 13-Apr-10 Apr-10 Aug-03

18 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

173 NCT00003810

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

CompletedDrug: docetaxel|Drug:

gemcitabine hydrochloride



(NCI)


Treatment1-Nov-99 Apr-99 23-Jul-08 Aug-04

181 NCT00002773

Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer

Completed

Biological: allogeneic tumor cell vaccine|Biological: recombinant

interferon alfa|Biological: sargramostim|Drug: cyclophosphamide

St. Vincent Medical Center - Los Angeles


Treatment1-Nov-99 Dec-08 6-Feb-09 Apr-07

296 NCT00003514

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Withdrawn

Drug: antineoplaston A10|Drug: antineoplaston AS2-

1|Procedure: alternative product therapy|Procedure: biological therapy|Procedure: biologically based therapies|Procedure:

cancer prevention intervention|Procedure:

complementary and alternative therapy|Procedure: differentiation therapy

Burzynski Research Institute


Treatment1-Nov-99 4-Dec-06 Dec-06

303 NCT00001228

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

Completed Drug: Interferon

National Institute of Diabetes and

Digestive and Kidney Diseases (NIDDK)


Treatment3-Nov-99 Oct-88 Sep-07 7-Sep-07 Sep-07

147 NCT00004190

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer


hydrochloride|Drug: oxaliplatin



(NCI)


Treatment21-Jan-00 Oct-99 23-Jul-08 Apr-07

205 NCT00004884

Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer


Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine

hydrochloride


Treatment of Cancer

Phase IIAllocation:


7-Mar-00 Jul-99 23-Jul-08 Jun-07

114 NCT00004895

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Completed Drug: octreotide acetate

Robert H. Lurie Cancer


(NCI)

Phase IIPrimary Purpose: Supportive Care

7-Mar-00 Oct-99 9-May-09 Nov-02

231 NCT00004861

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer


Drug: gemcitabine hydrochloride|Drug: tacedinaline

Pfizer Incorporated - Ann Arbor

Phase IIAllocation:


7-Mar-00 Oct-99 9-May-09 Jun-07

19 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

204 NCT00005053

Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer


Drug: glufosfamide


Treatment of Cancer

Phase IIAllocation:


6-Apr-00 Dec-99 23-Jul-08 Jun-07

131 NCT00005594ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

Completed Drug: ISIS 2503

University of Alabama at

Birmingham|National Cancer Institute

(NCI)|Isis Pharmaceuticals

Phase II 4




2-May-00 Jul-00 1-Dec-09 Dec-09 Dec-00

166 NCT00005591

Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas

CompletedBiological: cetuximab|Drug: gemcitabine hydrochloride



(NCI)


Treatment2-May-00 30-May-09 Apr-07

139 NCT00005832

R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer


Drug: tipifarnib


(NCI)


Treatment2-Jun-00 Jun-00 23-Jul-08 Apr-07

158 NCT00006117

Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer





Treatment3-Aug-00 Sep-99 29-Oct-09 Oct-09

159 NCT00006467

Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

CompletedDrug: ISIS 2503|Drug:

gemcitabine hydrochloride



(NCI)


Treatment6-Nov-00 Feb-01 23-Jul-08 Apr-07

211 NCT00010088

Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct


Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation:

radiation therapy



Treatment2-Feb-01 Jan-99 6-Feb-09 Apr-07

189 NCT00010062

Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer


Drug: fluorouracil|Radiation: radiation therapy



Treatment2-Feb-01 Oct-00 6-Feb-09 Apr-07

128 NCT00012246

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Completed

Biological: carcinoembryonic antigen peptide 1-6D|Biological:

incomplete Freund's adjuvant|Biological:

sargramostim

University of Texas|National Cancer Institute

(NCI)

Phase II


3-Mar-01 Jul-02 6-Feb-09 Jan-06

20 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

140 NCT00016965BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

Completed Drug: ixabepilone


(NCI)


Treatment6-Jun-01 Jul-01 23-Jul-08 Apr-03

259 NCT00019084

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Completed

Biological: aldesleukin|Biological: mutant p53 peptide pulsed dendritic cell vaccine|Biological: ras peptide cancer vaccine|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Biological:

therapeutic tumor infiltrating lymphocytes

National Cancer Institute (NCI)


Treatment11-Jul-01 Feb-96 6-Feb-09 Apr-07

169 NCT00019331

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Completed

Biological: aldesleukin|Biological: ras

peptide cancer vaccine|Biological:

sargramostim|Drug: DetoxPC



Treatment11-Jul-01 Oct-97 6-Feb-09 Apr-04

122 NCT00019474

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer


Biological: filgrastim|Biological: recombinant interferon

alfa|Drug: fluorouracil|Drug: hydroxyurea

Albert Einstein College of Medicine

of Yeshiva University|National Cancer Institute

(NCI)


Treatment11-Jul-01 Mar-98 6-Feb-09 Apr-07

294 NCT00019786

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases


Drug: isolated perfusion|Drug: melphalan|Procedure: conventional surgery


Phase II 67Masking: Open

Label|Primary Purpose: Treatment

11-Jul-01 Aug-99 6-Feb-09 Jan-06

155 NCT00024362

BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery


Drug: BBR 3464 Theradex Phase IIPrimary Purpose:

Treatment13-Sep-01 May-01 23-Jul-08 Apr-07

164 NCT00025168

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Completed

Drug: gemcitabine hydrochloride|Drug: irinotecan


Wake Forest University Baptist

Medical Center|National Cancer Institute

(NCI)


Treatment11-Oct-01 Nov-01 20-Aug-09 Aug-09

154 NCT00026130

Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer

Completed




(NCI)


Treatment9-Nov-01 Sep-01 9-Mar-10 Jul-04 Mar-10

21 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

161 NCT00026403

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer

Completed

Drug: cisplatin|Drug: gemcitabine




(NCI)


Treatment9-Nov-01 Sep-01 4-Aug-09 Jul-09 Jul-09

187 NCT00026104

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

Completed

Drug: gemcitabine hydrochloride|Drug: paclitaxel|Drug:

tipifarnib|Radiation: radiation therapy



(NCI)


Treatment9-Nov-01 Nov-01 6-Apr-10 Sep-03 Mar-10

182 NCT00028834

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

CompletedBiological: bevacizumab|Drug: gemcitabine hydrochloride

University of Chicago|National Cancer Institute

(NCI)

Phase IIMasking: Open


4-Jan-02 Feb-02 6-Feb-09 Oct-04

152 NCT00031694

Paclitaxel and Bryostatin-1 in Treating Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer


Drug: bryostatin 1|Drug: paclitaxel

Albert Einstein College of Medicine

of Yeshiva University|National Cancer Institute

(NCI)



8-Mar-02 Jan-02 23-Jul-08 Apr-04

123 NCT00033384

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

Completed Drug: CI-1040



(NCI)


Treatment9-Apr-02 Feb-02 30-May-09 Dec-02

90 NCT00040833

Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer

Completed

Procedure: complementary or alternative medicine

procedure|Procedure: pain therapy


(NCI)

Phase IIPrimary Purpose: Supportive Care

8-Jul-02 Feb-02 6-Feb-09 Jul-03

215 NCT00049348

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed

Biological: epoetin alfa|Biological: filgrastim|Drug:

cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Procedure:

adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation:

radiation therapy



(NCI)

Phase II


12-Nov-02 May-03 29-May-09 Jun-05 May-09

165 NCT00053222

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

Completed Drug: arsenic trioxide


(NCI)



27-Jan-03 Feb-03 23-Jul-08 Feb-04

22 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

151 NCT00053924Perifosine in Treating Patients With Advanced Pancreatic Cancer

Completed Drug: perifosine

Princess Margaret Hospital,

Canada|National Cancer Institute

(NCI)



5-Feb-03 May-03 23-Jul-08 Jul-04

107 NCT00059826

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer


Biological: recombinant interferon alfa|Drug:

cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Radiation: radiation

therapy

American College of Surgeons|National Cancer Institute

(NCI)



6-May-03 Mar-03 6-Feb-09 Jan-06

145 NCT00059982

Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Completed Drug: perifosine



(NCI)



6-May-03 Jul-03 23-Jul-08 Aug-04

226 NCT00062283Alanosine in Treating Patients With Cancer

Completed Drug: L-alanosine


(NCI)



5-Jun-03 Mar-03 11-Dec-09 Dec-09 Dec-05

198 NCT00064051

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer


hydrochloride|Drug: triapineVion Pharmaceuticals Phase II

Masking: Open Label|Primary Purpose:

Treatment8-Jul-03 Jan-03 23-Aug-08 Aug-08 Aug-06

108 NCT00068575

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

Recruiting


cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Radiation: radiation

therapy

M.D. Anderson Cancer


(NCI)



10-Sep-03 May-03 6-Feb-09 Jul-07

196 NCT00075647

CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed Drug: temsirolimus



(NCI)



9-Jan-04 Dec-03 23-Jul-08 Feb-05

237 NCT00078975

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer


Drug: gemcitabine hydrochloride|Drug: triapine



(NCI)



8-Mar-04 Apr-04 23-Jul-08 Nov-05

227 NCT00082862

Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

Recruiting


cisplatin|Drug: gemcitabine hydrochloride|Procedure: hyperthermia treatment

The University of Texas Health Science Center, Houston



14-May-04 Jul-02 14-Apr-09 Dec-08 Nov-12

23 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

190 NCT00085371

3-AP as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma (Cancer) of the Pancreas


Drug: triapineMayo Clinic|National Cancer Institute

(NCI)Phase II


Treatment10-Jun-04 Jul-04 4-Sep-09 Dec-05

202 NCT00089024

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer



leucovorin calcium|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation

therapy

University of Nebraska|National Cancer Institute

(NCI)



4-Aug-04 Feb-04 10-Mar-09 Mar-09 Dec-13

240 NCT00091026

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer


Biological: bevacizumab|Biological: cetuximab|Drug: erlotinib



(NCI)

Phase II 126


7-Sep-04 Sep-04 14-Apr-09 Dec-08

214 NCT00094445Trial of Curcumin in Advanced Pancreatic Cancer

Recruiting Drug: CurcuminM.D. Anderson Cancer Center

Phase II 50

Endpoint Classification: Safety/Efficacy


18-Oct-04 Nov-04 19-Feb-10 Feb-10 Nov-10

234 NCT00095966

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer


Drug: gemcitabine hydrochloride|Drug: sorafenib

tosylate


(NCI)



9-Nov-04 Sep-04 23-Jul-08 Jun-07 Sep-05

208 NCT00096070

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed

Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Radiation: radiation

therapy



(NCI)



9-Nov-04 Dec-04 10-Mar-09 Mar-09 Mar-09

262 NCT00109941

Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Completed Biological: opioid growth factorMilton S. Hershey Medical Center



3-May-05 Oct-03 6-Feb-09 Oct-07

179 NCT00111904

Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

CompletedDrug: paclitaxel-loaded

polymeric micelleTheradex Phase II 43


Treatment26-May-05 May-05 15-Dec-09 Jun-09 Aug-07

24 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

210 NCT00114179

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery


Biological: bevacizumab|Drug: capecitabine|Drug: gemcitabine




(NCI)



13-Jun-05 Jan-05 1-Aug-09 Feb-06

246 NCT00161187

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

RecruitingBiological: therapeutic allogeneic lymphocytes|Other: laboratory

biomarker analysis

Cancer Institute of New Jersey|National Cancer Institute

(NCI)

Phase II 40

Control: Active Control|Masking: Open Label|Primary Purpose:

Treatment

8-Sep-05 Dec-00 22-May-09 May-09

235 NCT00161213

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer


hydrochloride|Drug: imatinib mesylate

University of Medicine and Dentistry New Jersey|National Cancer Institute

(NCI)

Phase II 42

Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment

8-Sep-05 Sep-05 Jul-09 12-Nov-09 Nov-09 Jul-09

248 NCT00225784

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer


Drug: Erbitux/Gemcitabine|Procedure:

Radiotherapy

Dartmouth-Hitchcock Medical Center

Phase II 48

Allocation: Non-Randomized|Control:

Dose Comparison|Endpoint



22-Sep-05 Feb-05 19-Jan-09 Jan-09 Aug-08

201 NCT00238199

Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

CompletedDietary Supplement:

calcitriol|Drug: docetaxel

Oregon Health and Science

University|Sanofi-Aventis

Phase II 25

Endpoint Classification: Efficacy


12-Oct-05 Jun-02 Aug-06 6-Aug-09 Aug-09 Aug-06

25 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

133 NCT00253526

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn

Drug: bevacizumab|Drug: gemcitabine

hydrochloride|Procedure: adjuvant therapy|Procedure:

anti-cytokine therapy|Procedure: antiangiogenesis

therapy|Procedure: antibody therapy|Procedure: biological

therapy|Procedure: chemotherapy|Procedure:

conventional surgery|Procedure: growth factor antagonist

therapy|Procedure: monoclonal antibody therapy|Procedure:

surgery



Treatment11-Nov-05 4-Dec-06 Dec-06

191 NCT00262951

Combination Chemotherapy, Radiation Therapy, and Interferon Alfa in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Recruiting


cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation

therapy

Masonic Cancer Center, University of Minnesota|National Cancer Institute

(NCI)


Treatment6-Dec-05 Jan-05 6-Feb-09 Oct-08 Jan-10

264 NCT00275119

Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery


Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Radiation: radiation

therapy




10-Jan-06 Nov-03 6-Feb-09 Jan-06

225 NCT00276744

Individualized Drug Treatment Selection Process for Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Suspended

Biological: cetuximab|Drug: bortezomib|Drug: capecitabine|Drug:

docetaxel|Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride|Drug: irinotecan hydrochloride|Drug: mitomycin

C|Drug: sirolimus|Drug: thalidomide|Other: antitumor

drug screening assay|Procedure: conventional surgery

Sidney Kimmel Comprehensive

Cancer Center|National Cancer Institute

(NCI)



12-Jan-06 Oct-05 6-Nov-09 Jul-09 Apr-11

26 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

249 NCT00305760

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer


Biological: cetuximab|Biological: sargramostim plasmid DNA

pancreatic tumor cell vaccine|Drug:

cyclophosphamide|Other: laboratory biomarker

analysis|Procedure: biopsy



(NCI)



21-Mar-06 Dec-05 26-Feb-09 Feb-09 Dec-08

103 NCT00323583

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Recruiting

Drug: paclitaxel|Drug: oxaliplatin|Drug:

leucovorin|Drug: 5-fluorouracil|Drug:

glutathione|Drug: calcium and magnesium|Procedure:

Chemotherapy|Procedure: Chemoprotection|Procedure: Complementary and alternative

therapy

Seattle Cancer Treatment and Wellness Center

Phase II 80


Historical Control|Endpoint Classification: Safety/Efficacy


5-May-06 May-06 7-May-07 May-07

256 NCT00324428TMS for the Treatment of Pancreatic Cancer Pain


Procedure: Transcranial Magnetic Stimulation

Beth Israel Deaconess Medical Center|National

Institute of Diabetes and Digestive and Kidney Diseases

(NIDDK)

Phase II 32

Allocation: Non-Randomized|Endpoint


Study|Intervention Model: Crossover


10-May-06 May-06 Feb-08 3-Feb-10 Feb-10 Feb-08

253 NCT00335543

Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

Recruiting


hydrochloride|Procedure: adjuvant therapy|Procedure:

conventional surgery|Procedure: neoadjuvant therapy|Radiation:

radiation therapy

Interdisziplinare Arbeitsgruppe

Gastrointestinaler Tumore der Deutschen

Krebsgesellschaft

Phase II 254


8-Jun-06 Jun-03 4-Aug-09 Aug-09 Jun-09

220 NCT00376948

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed

Dietary Supplement: genistein|Drug: erlotinib



(NCI)



13-Sep-06 May-05 13-Apr-10 Apr-10 Mar-10

199 NCT00383760

E7389 as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Completed Drug: eribulin mesylate



(NCI)



29-Sep-06 Apr-06 7-Oct-09 Jul-09 Feb-09

192 NCT00389610

Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery


Biological: sargramostim plasmid DNA pancreatic tumor cell

vaccine

Sidney Kimmel Comprehensive Cancer Center



18-Oct-06 Sep-06 20-Jul-09 Mar-09 Dec-09

27 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

244 NCT00408564

Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery


Biological: cetuximab|Drug: capecitabine|Drug: gemcitabine

hydrochloride|Drug: oxaliplatin|Procedure:

conventional surgery|Procedure: neoadjuvant therapy|Radiation:

radiation therapy

Medical University of South Carolina



6-Dec-06 Jan-06 6-Feb-09 Nov-08 Jan-11

250 NCT00417976

Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer

RecruitingDrug: Gemcitabine|Drug:

Bevacizumab|Drug: Infusional 5-Fluorouracil

Ohio State University Comprehensive Cancer Center

Phase II 39


Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

2-Jan-07 Dec-06 27-Dec-07 Dec-07 Dec-09

274 NCT00425841

Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer

Recruiting

Drug: gemcitabine hydrochloride|Drug:

oxaliplatin|Procedure: adjuvant therapy|Procedure: neoadjuvant

therapy|Radiation: hypofractionated radiation

therapy|Radiation: stereotactic radiosurgery

Technische UniversitÃ¤t MÃ¼nchen



19-Jan-07 May-06 6-Feb-09 Jan-07

163 NCT00429858

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

SuspendedDrug: S-1|Drug: gemcitabine

hydrochloride

University of California, San

Francisco|National Cancer Institute

(NCI)

Phase II 100

Intervention Model: Single Group


30-Jan-07 Jan-07 Dec-11 19-Feb-10 Jun-09 Dec-10

101 NCT00020345

Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas





Treatment2-Mar-07 Sep-00 2-Mar-07 Dec-01

180 NCT00460174

Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer


Biological: bevacizumab|Drug: gemcitabine

hydrochloride|Procedure: conventional surgery|Radiation:

radiation therapy



(NCI)



11-Apr-07 Oct-05 18-Apr-09 Jan-09 Oct-07

207 NCT00462852

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Recruiting

Drug: dalteparin|Drug: gemcitabine

hydrochloride|Other: laboratory biomarker analysis

Hull and East Yorkshire Hospitals

NHS TrustPhase II 120

Allocation: Randomized|Primary Purpose: Treatment

18-Apr-07 Apr-03 9-May-09 Apr-07

28 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

92 NCT00470535Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer


Drug: erlotinib hydrochloride|Other:

immunohistochemistry staining method|Other: laboratory

biomarker analysis

Roswell Park Cancer Institute|National Cancer Institute

(NCI)



3-May-07 Jan-07 15-Apr-09 Apr-09 May-11

171 NCT00482625

Erlotinib in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Recruiting Drug: Erlotinib

University of California,

Irvine|National Cancer Institute

(NCI)

Phase II 30



4-Jun-07 May-06 Dec-12 13-Apr-10 Apr-10 Dec-11

137 NCT00499486Sirolimus in Treating Patients With Advanced Pancreatic Cancer


Drug: sirolimus|Genetic: polymorphism analysis|Genetic:

reverse transcriptase-polymerase chain reaction|Other:


biomarker analysis|Other: liquid chromatography|Other: mass

spectrometry|Other: pharmacological

study|Procedure: biopsy



(NCI)


Treatment10-Jul-07 Jan-05 7-Feb-09 Feb-09

129 NCT00499265

Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery


Drug: gemcitabine hydrochloride|Drug: serine protease inhibitor WX-671

Wilex Phase II 90


10-Jul-07 Apr-07 22-Oct-08 Apr-08

241 NCT00536874

Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Recruiting

Drug: gemcitabine hydrochloride|Drug:

oxaliplatin|Genetic: protein expression analysis|Genetic: proteomic profiling|Other: laboratory biomarker

analysis|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant

therapy


(NCI)

Phase II 37


27-Sep-07 Oct-07 7-Jul-09 Jul-09 Oct-10

150 NCT00550004

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

TerminatedDrug: RP101|Drug: Gemcitabine

(1000 mg/m2)SciClone

PharmaceuticalsPhase II 153





Caregiver, Investigator)|Primary

Purpose: Health Services Research

25-Oct-07 Sep-07 Oct-09 12-Oct-09 Oct-09 Aug-09

29 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

290 NCT00569387Vaccine Study for Surgically Resected Pancreatic Cancer

RecruitingBiological: HyperAcute(R)-Pancreatic Cancer Vaccine

NewLink Genetics Corporation

Phase II 71


Historical Control|Endpoint

Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

5-Dec-07 Dec-07 Apr-10 12-Feb-10 Feb-10 Apr-10

261 NCT00570713An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer


Drug: MORAb-009|Drug: Gemcitabine

Morphotek Phase II 152


Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

7-Dec-07 Dec-07 Mar-10 23-Mar-09 Mar-09

219 NCT00599833

Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

RecruitingBiological: cetuximab|Radiation:

3-dimensional conformal radiation therapy

Christie Hospital NHS Foundation Trust



11-Jan-08 May-07 21-Aug-09 Aug-09 May-12

177 NCT00601627

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

Recruiting

Biological: panitumumab|Drug: capecitabine|Drug:

fluorouracil|Drug: gemcitabine hydrochloride|Radiation:

radiation therapy



(NCI)



18-Jan-08 Jun-09 10-Apr-10 Apr-10 Dec-09

184 NCT00691054

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Did Not Respond to First-Line Therapy With Gemcitabine


Drug: paclitaxel albumin-stabilized nanoparticle

formulation

University of Miami Sylvester

Comprehensive Cancer Center



4-Jun-08 Jun-08 11-Jan-10 Jan-10 Jun-15

142 NCT00710710

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Completed Drug: BI 2536Boehringer Ingelheim Pharmaceuticals

Phase II 89

Endpoint Classification: Efficacy


Assignment|Primary Purpose: Treatment

3-Jul-08 Aug-06 28-May-09 May-09 Oct-08

30 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

193 NCT00837876

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Recruiting

Drug: erlotinib hydrochloride|Drug: sorafenib

tosylate|Genetic: DNA analysis|Genetic: gene

expression analysis|Genetic: polymorphism analysis|Genetic:

proteomic profiling|Other: laboratory biomarker analysis

Vanderbilt-Ingram Cancer


(NCI)

Phase II 47


5-Feb-09 Oct-08 24-Dec-09 Dec-09 Jun-15

242 NCT00882765

Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Not yet recruiting

Dietary Supplement: genistein|Procedure: therapeutic

conventional surgery

Jonsson Comprehensive


(NCI)

Phase II 30


15-Apr-09 Apr-09 8-Jan-10 Jun-09 Apr-10

100 NCT00966706

Cisplatin, Capecitabine, Gemcitabine Hydrochloride and Epirubicin Hydrochloride or Docetaxel in Treating Patients With Stage III or Stage IV Pancreatic Cancer

Recruiting

Drug: capecitabine|Drug: cisplatin|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: gemcitabine hydrochloride

Istituto Scientifico H. San Raffaele

Phase II 104


26-Aug-09 Jun-05 29-Sep-09 Aug-09 Aug-08

301 NCT00983541

Definitive Chemoradiation With Gemcitabine and Continuous Fluorouracil (5- FU) Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma

RecruitingDrug: Gemcitabine|Drug:

Fluorouracil (5-FU)|Radiation: Brachytherapy or SBRT

University of Utah Phase II 12



22-Sep-09 Sep-09 Sep-11 19-Mar-10 Mar-10 Sep-11

291 NCT01010126

Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

RecruitingBiological: bevacizumab|Drug: temsirolimus|Other: laboratory

biomarker analysis


(NCI)Phase II 275


Treatment6-Nov-09 Sep-09 2-Apr-10 Apr-10 Dec-12

167 NCT01032057

Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Recruiting

Drug: capecitabine|Drug: gemcitabine

hydrochloride|Procedure: quality-of-life assessment|Radiation: 3-dimensional conformal radiation

therapy

Wales Cancer Trials Unit

Phase II 102


13-Dec-09 Jul-09 13-Dec-09 Dec-09 Jul-11

31 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

95 NCT01065870

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Recruiting

Drug: Neoadjuvant gemcitabine, capecitabine, and

docetaxel|Drug: Gemcitabine, capecitabine, docetaxel followed

by radiotherapy

Columbia University Phase II 64





8-Feb-10 Dec-09 Dec-13 13-Apr-10 Apr-10 Dec-12

149 NCT00003332

Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer



hydrochloride|Procedure: surgical procedure|Radiation:

radiation therapy

New York University School of


(NCI)

Phase I|Phase II

36Primary Purpose:

Treatment1-Nov-99 Jul-97 6-Feb-09 Apr-04

113 NCT00004910

Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction


Procedure: bowel obstruction management|Procedure: quality-

of-life assessment



(NCI)

Phase I|Phase II


7-Mar-00 Jan-00 9-May-09 May-00

299 NCT00227617

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

RecruitingBiological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin



(NCI)

Phase I|Phase II

102Masking: Open


26-Sep-05 Jun-05 14-Jan-10 Jan-07 Dec-09

136 NCT00260364

Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer


Drug: Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day

cycle|Drug: Capecitabine orally days 1 -21|Drug: Erlotinib 100 mg orally days 1-28|Drug: Bevacizumab 5 mg/kg

intravenously every 2 weeks

Royal Marsden NHS Foundation

Trust|Professor Cunningham's Clinical Research Fund|Hoffmann-La

Roche

Phase I|Phase II

40

Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

29-Nov-05 Nov-05 Dec-09 5-Jan-10 Jan-10

135 NCT00265876

AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery


Drug: AZD0530|Drug: gemcitabine hydrochloride


Phase I|Phase II

60Masking: Open


14-Dec-05 Sep-05 5-Mar-10 Mar-10 Jun-09

236 NCT00281996

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer


hydrochloride|Drug: imatinib mesylate



(NCI)

Phase I|Phase II

43Masking: Open


24-Jan-06 Mar-05 23-Jul-08 Apr-06 May-06

32 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

195 NCT00410774

Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery


Biological: bevacizumab|Drug: gemcitabine

hydrochloride|Procedure: adjuvant therapy



(NCI)

Phase I|Phase II

20


11-Dec-06 Jul-06 6-Feb-09 Aug-08 Oct-07

109 NCT00529984

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies


Biological: AVX701|Biological: AVX701|Biological: AVX701|Biological:

AVX701|Biological: AVX701

AlphaVax, Inc.|Duke University

Phase I|Phase II

36




12-Sep-07 Sep-07 May-10 20-Aug-09 Aug-09 May-10

268 NCT00553683

3-Dimensional Conformal Radiation Therapy, Arterial Embolization, and Tumor Cell Vaccine in Treating Patients With Unresectable, Recurrent, or Metastatic Primary Liver Cancer or Pancreatic Cancer

Recruiting

Drug: poly ICLC|Procedure: biopsy|Procedure: hepatic artery

embolization|Radiation: 3-dimensional conformal radiation

therapy

University of Medicine and

Dentistry New Jersey

Phase I|Phase II

40Masking: Open


2-Nov-07 Oct-07 7-Jul-09 Jul-09 Oct-09

245 NCT00637364

High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain

SuspendedProcedure: High intensity focused ultrasound, HIFU

CMED HIFU Development Corporation

Phase I|Phase II

5

Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

12-Mar-08 Mar-08 12-Jan-09 Jan-09 Jul-10

230 NCT00735306

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Recruiting Drug: Avastin and TarcevaDuke

University|GenentechPhase I|Phase

II34




13-Aug-08 Jul-08 Dec-11 15-Sep-09 Sep-09 Dec-10

212 NCT00878657

Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer

Recruiting

Drug: gemcitabine hydrochloride|Procedure:

adjuvant therapy|Radiation: intensity-modulated radiation

therapy


(NCI)

Phase I|Phase II

50Allocation: Non-


8-Apr-09 Apr-09 18-Apr-09 Apr-09 Mar-13

33 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

229 NCT01017822

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Not yet recruiting

Biological: conatumumab|Drug: capecitabine|Drug: gemcitabine hydrochloride|Radiation: 3-

dimensional conformal radiation therapy



(NCI)

Phase I|Phase II

89Masking: Open


20-Nov-09 Nov-09 26-Mar-10 Mar-10 Nov-10

228 NCT00002854

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer


Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug:

cyclophosphamide|Drug: etoposide|Drug:

ifosfamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation

City of Hope Medical Center|National Cancer Institute

(NCI)

Phase I 6Primary Purpose:

Treatment1-Nov-99 Dec-94 11-Jan-10 Jan-10

295 NCT00002947

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer


Radiation: indium In 111 pentetreotide

Yale University|National Cancer Institute

(NCI)


Treatment1-Nov-99 Oct-96 26-Apr-09 May-07

153 NCT00003426

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer




(NCI)

Phase IPrimary Purpose:

Treatment1-Nov-99 Apr-98 6-Feb-09 Jun-02

157 NCT00003411

Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer

CompletedDrug: motexafin

gadolinium|Radiation: radiation therapy

University of Pittsburgh|National Cancer Institute

(NCI)


Treatment1-Nov-99 Nov-98 26-Dec-09 Apr-07

176 NCT00003867Irinotecan and Capecitabine in Treating Patients With Solid Tumors


Drug: capecitabine|Drug: irinotecan hydrochloride

Albert Einstein College of Medicine of Yeshiva University


Treatment1-Nov-99 Mar-99 23-Jul-08 Apr-07

178 NCT00003798

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery

CompletedDrug: motexafin

gadolinium|Radiation: radiation therapy



(NCI)


Treatment1-Nov-99 Apr-00 9-Mar-10 Mar-10

168 NCT00004074

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

CompletedBiological: recombinant interleukin-12|Biological:

trastuzumab

Arthur G. James Cancer Hospital & Richard J. Solove

Research Institute|National Cancer Institute

(NCI)


Treatment10-Dec-99 Jul-99 6-Feb-10 Mar-09 Feb-09

172 NCT00004178Gene Therapy in Treating Patients With Cancer


Biological: therapeutic autologous lymphocytes

Beth Israel Deaconess Medical

CenterPhase I


21-Jan-00 Apr-98 6-Feb-09 May-06

217 NCT00004604Biological Therapy in Treating Patients With Metastatic Cancer


Biological: carcinoembryonic antigen RNA-pulsed DC cancer

vaccine


(NCI)


Treatment2-May-00 Feb-97 6-Feb-09 Apr-07

34 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

111 NCT00005858

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-Small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

Completed Biological: LMB-9 immunotoxin

University of Maryland

Greenebaum Cancer Center|National Cancer Institute

(NCI)


Treatment2-Jun-00 Apr-00 6-Feb-09 Mar-03

185 NCT00005842

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

CompletedBiological: trastuzumab|Drug:

tipifarnib

University of Texas|National Cancer Institute

(NCI)


Treatment2-Jun-00 Jun-00 29-Aug-09 Apr-07

293 NCT00006368

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer


Radiation: yttrium Y 90-edotreotide

H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute

(NCI)


Treatment4-Oct-00 Nov-99 6-Feb-09 Oct-01

110 NCT00006981Immunotoxin Therapy in Treating Patients With Advanced Cancer

CompletedBiological: SS1(dsFv)-PE38

immunotoxinNational Cancer Institute (NCI)

Phase IMasking: Open


6-Dec-00 Dec-00 9-Jan-10 May-05

174 NCT00008099

Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer


Biological: MUC-1 antigen/SB AS-2

University of Pittsburgh|National Cancer Institute

(NCI)


Treatment6-Jan-01 May-98 29-Jul-09 Apr-07

183 NCT00010023

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors


Drug: capecitabine|Drug: cisplatin

New York University School of


(NCI)


Treatment2-Feb-01 Aug-00 23-Jul-08 Dec-05

120 NCT00010270

LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer


Biological: LMB-9 immunotoxin

University Hospital Freiburg|National Cancer Institute

(NCI)


Treatment2-Feb-01 Apr-01 6-Feb-09 Jan-07

132 NCT00014456

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors


Biological: filgrastim|Drug: docetaxel|Drug: gemcitabine

hydrochloride

Norris Cotton Cancer Center|National Cancer Institute

(NCI)


Treatment10-Apr-01 Mar-00 6-Feb-09 Nov-04

216 NCT00020579

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed Drug: entinostatNational Cancer Institute (NCI)

Phase I 75Masking: Open


11-Jul-01 Mar-01 13-Mar-10 Feb-07 Apr-08

115 NCT00024063SU006668 in Treating Patients With Advanced Solid Tumors


Drug: SU6668

Jonsson Comprehensive


(NCI)


Treatment13-Sep-01 16-Nov-08 Apr-07

35 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

119 NCT00025532

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

CompletedOther: iodine I 131 monoclonal

antibody CC49-deltaCH2



(NCI)


Treatment11-Oct-01 Apr-01 6-Feb-09 Apr-07

170 NCT00027521

Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer


Biological: bleomycin sulfate|Drug: electroporation

therapy

Ichor Medical Systems

Incorporated|National Cancer Institute

(NCI)


Treatment7-Dec-01 Dec-00 18-Apr-09 Jul-02

117 NCT00027534

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

Completed

Biological: CMV pp65 peptide|Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Biological: tetanus toxoid|Biological: therapeutic autologous dendritic cells


(NCI)


Treatment7-Dec-01 Jan-02 6-Feb-09 Sep-05

118 NCT00028496

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Completed

Biological: recombinant fowlpox GM-CSF vaccine

adjuvant|Biological: recombinant fowlpox-CEA(6D)/TRICOM

vaccine|Biological: sargramostim

Fox Chase Cancer Center|National Cancer Institute

(NCI)


Treatment4-Jan-02 Jan-02 6-Feb-09 Aug-03

223 NCT00030498

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Completed Drug: erlotinib hydrochloride


(NCI)


Treatment14-Feb-02 Dec-01 10-Sep-09 Dec-08 Jul-07

148 NCT00033241

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

CompletedDrug: erlotinib


OSI Pharmaceuticals Phase IPrimary Purpose:

Treatment9-Apr-02 Jun-01 23-Jul-08 Dec-03

156 NCT00039403

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

CompletedDrug: 7-

hydroxystaurosporine|Drug: gemcitabine hydrochloride



(NCI)


Treatment6-Jun-02 May-02 23-Jul-08 Jan-06

143 NCT00047307

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed

Drug: alvocidib|Drug: gemcitabine



(NCI)


Treatment3-Oct-02 Aug-02 6-Feb-09 Mar-08 Aug-08

298 NCT00049023

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

RecruitingRadiation: yttrium Y 90-

edotreotide

Holden Comprehensive


(NCI)


Treatment12-Nov-02 Jan-02 6-Feb-09 Apr-08

36 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

121 NCT00049608

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors


Dietary Supplement: mistletoe extract|Drug: gemcitabine

hydrochloride

National Center for Complementary and Alternative Medicine (NCCAM)|National Cancer Institute

(NCI)



12-Nov-02 Jul-02 6-Feb-09 Apr-07

194 NCT00049296Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

CompletedDrug: docetaxel|Drug:

thalidomide

Case Comprehensive Cancer


(NCI)

Phase I 26



12-Nov-02 Jul-02 Jan-06 23-Feb-10 Feb-10 Dec-04

209 NCT00063947

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Completed

Drug: erlotinib hydrochloride|Drug: gemcitabine



(NCI)



8-Jul-03 Jun-03 11-Feb-09 Nov-06 Jan-09

222 NCT00077519

Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer


Drug: tipifarnib|Radiation: radiation therapy

University of Pennsylvania|National Cancer Institute

(NCI)


Treatment10-Feb-04 Jan-04 6-Feb-09 Apr-07

112 NCT00101348

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Completed

Biological: bevacizumab|Biological: cetuximab|Drug: erlotinib

hydrochloride

Institute for Drug Development|National Cancer Institute

(NCI)



7-Jan-05 Jan-05 6-Feb-09 Nov-06 Jul-08

288 NCT00121745

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Terminated

Genetic: Rexin-G Dose 1|Genetic: Rexin-G Dose 2|Genetic: Rexin-G Dose 3|Genetic: Rexin-G Dose 4

Epeius Biotechnologies

Phase I 12





15-Jul-05 Jul-05 Jul-07 15-Dec-07 Dec-07

247 NCT00266097

Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer



hydrochloride|Drug: oxaliplatin|Radiation: radiation

therapy

UNC Lineberger Comprehensive


(NCI)

Phase I 110

Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment

13-Dec-05 Aug-04 26-Nov-09 Nov-09 Mar-09

37 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

102 NCT00288093

3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery

RecruitingDrug: triapine|Radiation:

radiation therapy

Arthur G. James Cancer Hospital & Richard J. Solove

Research Institute|National Cancer Institute

(NCI)


Treatment6-Feb-06 Dec-06 2-Feb-10 Jun-07 Aug-07

203 NCT00310050

Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed

Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium|Radiation: radiation

therapy

Wake Forest University|National Cancer Institute

(NCI)

Phase I 33


29-Mar-06 Oct-05 6-Feb-09 Apr-08 May-08

186 NCT00352131

Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

Completed Drug: HuC242-DM4 ImmunoGen, Inc. Phase I 50




13-Jul-06 Feb-05 Dec-09 16-Mar-10 Mar-10 Dec-09

89 NCT00019006

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

CompletedDrug: Detox-B adjuvant|Drug: ras peptide cancer vaccine



Treatment1-Mar-07 Mar-95 1-Mar-07 May-05

175 NCT00462553

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors


Drug: gemcitabine hydrochloride|Drug: sunitinib

malate



(NCI)

Phase I 37



18-Apr-07 Mar-07 13-Apr-10 Apr-10 Mar-10

243 NCT00467116

Gemcitabine, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery


Biological: cetuximab|Drug: gemcitabine




(NCI)


Treatment25-Apr-07 Oct-05 6-Feb-09 Oct-08 Oct-10

273 NCT00515866

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer


Drug: KU-0059436 (AZD2281)(PARP

inhibitor)|Drug: Gemcitabine

AstraZeneca|KuDOS Pharmaceuticals

LimitedPhase I 95





13-Aug-07 Aug-07 Aug-10 12-Apr-10 Apr-10 Aug-10

38 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

138 NCT00544193

Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer


Drug: gemcitabine hydrochloride|Genetic: polymerase chain reaction|Other:

immunohistochemistry staining method|Procedure: conventional

surgery|Radiation: intraoperative radiation

therapy|Radiation: radiation therapy

City of Hope Medical Center|National Cancer Institute

(NCI)


Treatment13-Oct-07 Dec-97 13-Jan-10 Jan-10

134 NCT00547612

Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

Completed

Other: high performance liquid chromatography|Other:

pharmacological study|Radiation: [18F]-labeled substance P antagonist receptor

quantifier


Phase I 33

Allocation: Non-Randomized|Control: Uncontrolled|Primary Purpose: Diagnostic

19-Oct-07 Sep-07 7-Feb-09 Nov-08 Dec-08

266 NCT00565487

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

Recruiting Drug: Capecitabine, TarcevaPenn State

University|GenentechPhase I 27





29-Nov-07 Dec-07 Dec-10 9-Feb-10 Feb-10 Jan-10

106 NCT00654160

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

Recruiting

Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Other:

pharmacogenomic studies|Other: pharmacological

study


(NCI)Phase I 70


4-Apr-08 Jun-08 4-Aug-09 Aug-09 Jun-15

188 NCT00669734

Vaccine Therapy and GM-CSF in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

RecruitingBiological: falimarev|Biological:

inalimarev|Biological: sargramostim


(NCI)


Treatment29-Apr-08 Feb-10 4-Feb-10 Aug-08 Aug-10

300 NCT00692640

Safety Study of XL147 in Combination With Erlotinib in Adults With Solid Tumors

Recruiting Drug: XL147|Drug: Erlotinib Exelixis Phase I 65

Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

3-Jun-08 May-08 Oct-09 20-Oct-08 Oct-08 Oct-09

39 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

57 NCT00703625

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies


Drug: temsirolimus & docetaxelWashington

University School of Medicine

Phase I 25



20-Jun-08 Mar-08 15-Sep-09 Sep-09 Mar-10

130 NCT00703638

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

RecruitingDrug: cisplatin|Drug:

pemetrexed disodium|Drug: sorafenib tosylate

Masonic Cancer Center, University of Minnesota|National Cancer Institute

(NCI)


Treatment20-Jun-08 May-08 4-Mar-10 Mar-10 Jun-11

83 NCT00843830

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

Suspended

Radiation: tumoral irradiation|Biological: Dendritic cell vaccination|Biological:

Additional cycles

University of Michigan Cancer

CenterPhase I 6




12-Feb-09 Oct-06 Jun-15 19-Feb-10 Feb-10 Jun-14

239 NCT00885066

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

RecruitingDrug: capecitabine|Drug:

erlotinib hydrochloride|Drug: gemcitabine hydrochloride

Centre Antoine Lacassagne

Phase I 30Allocation: Non-


18-Apr-09 May-08 23-Dec-09 Jul-09 Mar-10

160 NCT00983268

Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

Recruiting

Drug: capecitabine|Drug: vorinostat|Other: laboratory biomarker analysis|Procedure: diffusion-weighted magnetic resonance imaging|Radiation: hypofractionated radiation

therapy


Center|National Cancer Institute (NCI)|National Comprehensive Cancer Network


Treatment23-Sep-09 Oct-09 4-Nov-09 Oct-09 May-15

200 NCT00987766

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Recruiting


hydrochloride|Drug: oxaliplatin|Other: laboratory

biomarker analysis



(NCI)


Treatment30-Sep-09 Nov-09 17-Nov-09 Nov-09 Jan-16

224 NCT01025882

Stereotactic Body Radiation Therapy With or Without Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Recruiting

Drug: gemcitabine hydrochloride|Radiation: stereotactic body radiation

therapy

Simmons Cancer Center


Treatment3-Dec-09 Oct-09 3-Dec-09 Oct-09 Oct-14

40 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

104 NCT01068327

Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer

Recruiting

Drug: gemcitabine hydrochloride|Drug: leucovorin calcium|Drug: fluorouracil|Drug: nelfinavir mesylate|Radiation: stereotactic body radiation

therapy|Radiation: hypofractionated radiation

therapy|Procedure: therapeutic conventional surgery|Other:

pharmacological study|Genetic: polymorphism analysis|Other:

pharmacogenomic studies|Genetic: protein expression analysis

University of Nebraska

Phase I 36

Endpoint Classification: Safety


25-Jan-10 Nov-07 30-Mar-10 Mar-10 Dec-12

116 NCT01096199A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

Not yet recruiting

Drug: TS-ONE, Cisplatin, RAD001

National University Hospital, Singapore

Phase I 35 29-Mar-10 30-Mar-10 Mar-10

126 NCT00003851

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer


Biological: proteolytic enzymes|Drug: gemcitabine hydrochloride|Procedure:

Gonzalez regimen

Herbert Irving Comprehensive

Cancer Center|National Center for

Complementary and Alternative Medicine

(NCCAM)

90Masking: Open


1-Nov-99 Mar-99 15-Sep-09 Dec-05

269 NCT00006253

Conventional Care With or Without Specialized Cancer Care in Treating Patients Receiving Chemotherapy


Procedure: management of therapy

complications|Procedure: psychosocial assessment and care|Procedure: quality-of-life

assessment

University of Michigan Cancer Center|National Cancer Institute

(NCI)


11-Sep-00 Aug-00 19-Aug-09 Apr-07

272 NCT00079365

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas



hydrochloride|Radiation: brachytherapy|Radiation: phosphorus P32|Radiation:

radiation therapy

University of South Florida


8-Mar-04 May-01 6-Feb-09 May-05

284 NCT00087191

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

CompletedDrug: EF5|Drug: motexafin

lutetium

University of Pennsylvania|National Cancer Institute

(NCI)


Diagnostic8-Jul-04 May-04 23-Jul-08 Dec-05

41 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

281 NCT00253383

Early Intervention Palliative Care or a Standard Palliative Care Program in Improving End-of-Life Care in Patients With Advanced Lung, Gastrointestinal, Genitourinary, or Breast Cancer


Other: counseling intervention|Other: educational

intervention|Procedure: psychosocial assessment and care|Procedure: quality-of-life

assessment

Norris Cotton Cancer Center|National Cancer Institute

(NCI)

450 Allocation: Randomized 11-Nov-05 Jan-03 12-Sep-09 Nov-08 Jun-08

277 NCT00369460Changes in Muscle Tissue in Patients With Pancreatic Cancer

Completed Other: physiologic testing



(NCI)

9Observational Model:

Cohort|Time Perspective: Prospective

24-Aug-06 Jan-06 Jul-09 16-Apr-10 Apr-10 Jul-09

258 NCT00369109

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

Completed

Other: biologic sample preservation procedure|Other: immunohistochemistry staining method|Other: laboratory

biomarker analysis|Procedure: biopsy


(NCI)

60 24-Aug-06 Feb-06 9-May-09 Mar-07

265 NCT00398164

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer


Drug: aprepitant|Drug: capecitabine|Drug:

fluorouracil|Drug: gemcitabine hydrochloride|Procedure: quality-of-life assessment|Radiation:

radiation therapy


(NCI)

57

Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Supportive

Care

9-Nov-06 Aug-06 22-Dec-09 Oct-09 Jan-09

263 NCT00433602

Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors


Other: clinical observation|Procedure: management of therapy complications|Procedure:

ultrasound imaging


Treatment of Cancer

2000 8-Feb-07 Nov-06 13-Dec-09 Apr-07

232 NCT00436410

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

Completed

Biological: colloidal gold-bound tumor necrosis factor|Other: electron microscopy|Other:

pharmacological study|Procedure: conventional

surgery


108Primary Purpose:

Treatment15-Feb-07 Dec-06 27-Aug-09 Nov-08 Aug-09

267 NCT00448838

Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer


Biological: cetuximab|Drug: gemcitabine hydrochloride|Drug:

oxaliplatin

University of Miami Sylvester

Comprehensive Cancer Center

40


15-Mar-07 May-06 11-Jan-10 Jan-10 May-13

218 NCT00452946

Biomarkers and Radiation Side Effects in Patients Undergoing Radiation Therapy for Gastrointestinal Cancer

Recruiting

Genetic: DNA methylation analysis|Genetic: mutation analysis|Genetic: polymerase chain reaction|Other: laboratory biomarker analysis|Procedure:

assessment of therapy complications


120Primary Purpose: Supportive Care

27-Mar-07 Feb-07 22-Dec-09 Jun-09

42 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

87 NCT00478010

Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer


Other: counseling intervention|Other: study of

socioeconomic and demographic variables|Procedure:


assessment



(NCI)

200Masking: Open

Label|Primary Purpose: Health Services Research

23-May-07 Jan-07 20-Jul-09 Feb-09 Dec-08

213 NCT00489515

Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder


Drug: isosulfan blue|Other: immunohistochemistry staining method|Other: laboratory

biomarker analysis|Procedure: conventional surgery|Procedure: lymphadenectomy|Procedure: lymphangiography|Procedure: sentinel lymph node biopsy


(NCI)

125Primary Purpose:

Diagnostic20-Jun-07 Feb-99 18-Sep-09 Sep-09 Dec-10

289 NCT00499733

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Recruiting

Drug: cyclophosphamide|Other: laboratory biomarker analysis|Procedure:

biopsy|Procedure: cryosurgery



(NCI)

23Primary Purpose:

Treatment10-Jul-07 Jun-07 3-Jul-09 Jul-09 Jul-10

43 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

297 NCT00561990Nimotuzumab in Adults With Pancreatic Cancer

Recruiting

Oncoscience AG|Marienhospital Herne, Abt. fÃ¼r HÃ¤matologie und Onkologie, Herne, Germany|University

of Kiel|Gemeinschaftspr

axis fÃ¼r HÃ¤matologie und Onkologie, KÃ¶ln,

Germany|Onkologisches Zentrum III, Medizinische Klinik,

Mannheim, Germany|Onkologisc

he Gemeinschaftspraxis,

MÃ¼lheim, Germany|II.

Medizinische Klinik u. Poliklinik, Klinikum rechts der Isar, MÃ¼nchen,

Germany|HÃ¤matologisch-Onkologische Schwerpunktpraxis,

MÃ¼nster, Germany|Praxis fÃ¼r

Internistische Onkologie und HÃ¤matologie, Recklinghausen,

Germany

188Observational Model: Case Control|Time

Perspective: Prospective20-Nov-07 Sep-07 Sep-10 3-Feb-10 Feb-10

260 NCT00658424

CBT-1 and Paclitaxel in Treating Patients With Refractory, Recurrent, or Advanced Metastatic Solid Tumors

RecruitingDrug: MDR modulator CBT-

1|Drug: paclitaxel|Radiation: Tc 99m sestamibi


12Primary Purpose:

Treatment12-Apr-08 Sep-07 6-Feb-09 Apr-08 Sep-08

275 NCT00660348

Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Suspended

Drug: bupivacaine hydrochloride|Drug:

clonidine|Drug: morphine sulfate|Procedure: assessment

of therapy complications|Procedure: quality-

of-life assessment



(NCI)

80

Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive

Care

16-Apr-08 Mar-08 6-Nov-09 Jul-09 Dec-10

44 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

271 NCT00661882

Computer Tools for Improving Early Diagnosis and Treatment in Healthy Volunteers or Patients With Pancreatic Cancer or Who Are At Risk For Pancreatic Cancer or Who Have a Noncancer Pancreatic Disorder

Recruiting

Other: medical chart review|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: biopsy

University of Nebraska|National Cancer Institute

(NCI)

240 18-Apr-08 Feb-03 16-Jun-09 Jun-09 Dec-12

162 NCT00684801

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

RecruitingOther: questionnaire

administration|Procedure: quality-of-life assessment



(NCI)

744

Allocation: Non-Randomized|Intervention

Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive

Care

23-May-08 Aug-07 16-Apr-10 Apr-10 Nov-10

287 NCT00706290

Cognitive and Behavioral Therapy or Standard Care in Patients With Advanced Gastrointestinal Cancer or Lung Cancer

Recruiting

Other: counseling intervention|Other: educational

intervention|Other: questionnaire

administration|Procedure: meditation therapy|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment|Procedure: standard

follow-up care

Massachusetts General

Hospital|National Cancer Institute

(NCI)

60Allocation:

Randomized|Control: Active Control

26-Jun-08 Apr-07 14-Jul-09 Jul-09 Mar-10

99 NCT00769652

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

Terminated

Behavioral: compliance monitoring|Dietary Supplement: dietary intervention|Dietary Supplement: nutritional intervention|Drug:

chemotherapy|Other: counseling intervention|Other: medical

chart review|Other: questionnaire

administration|Other: study of socioeconomic and demographic

variables|Procedure: management of therapy complications|Procedure:

observation|Procedure: quality-of-life assessment

University of Medicine and Dentistry New Jersey|National Cancer Institute

(NCI)

230

Allocation: Randomized|Primary Purpose: Supportive

Care

8-Oct-08 Oct-06 Aug-09 10-Dec-09 Dec-09 Aug-09

50 NCT00786058

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

Approved for marketing

Drug: OFF in experimental arm

CONKO-Studiengruppe|Sanofi-

Aventis|medac GmbH|Amgen

4-Nov-08 12-Jun-09 Jun-09

257 NCT00830557

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

Recruiting

Other: medical chart review|Other: survey

administration|Procedure: study of high risk factors


(NCI)5000 27-Jan-09 Oct-00 16-Mar-10 Dec-08

45 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

74 NCT00896467

Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy

Recruiting

Other: questionnaire administration|Procedure:


assessment

Centre Oscar Lambret

200 8-May-09 Sep-07 7-Jul-09 Jul-09 Sep-10

285 NCT00897494

Identification of Biomarkers for Early Detection of Pancreatic Cancer


Genetic: protein expression analysis|Other: laboratory

biomarker analysis|Other: mass spectrometry|Other: surface-

enhanced laser desorption/ionization-time of flight mass spectrometry


(NCI)

120 9-May-09 Feb-05 17-Nov-09 Nov-09

254 NCT00898482

Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants


Other: physiologic testing|Other: study of socioeconomic and demographic variables



(NCI)

400 9-May-09 May-05 5-Nov-09 Jul-09 Dec-10

278 NCT00899158

Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss

Completed

Other: immunologic technique|Other: laboratory biomarker analysis|Procedure:

biopsy



(NCI)

44

Observational Model: Case-Only|Time

Perspective: Cross-Sectional

9-May-09 Jun-05 Dec-08 16-Apr-10 Apr-10 Nov-08

280 NCT00899496

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

RecruitingOther: immunological diagnostic method|Other: physiologic

testing


(NCI)

48 9-May-09 Jul-05 10-Mar-10 Jun-09

302 NCT00898729Tumor Angiogenesis in Patients With Endocrine Tumors

Completed

Genetic: DNA methylation analysis|Genetic: in situ hybridization|Genetic:

microarray analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other:


biomarker analysis|Procedure: biopsy


400 9-May-09 Jan-07 7-Oct-09 Nov-08 Sep-09

282 NCT00900003Studying Biomarkers in Patients With Pancreatic Cancer

RecruitingGenetic: protein analysis|Other: laboratory biomarker analysis



(NCI)

9-May-09 May-07 11-Aug-09 Oct-08 May-12

46 of 47 4/20/2010, 8:16 PM



tStudy Designs

First Received


DateLast

UpdatedLast

Verified

Primary Completion

Date

276 NCT00900094

Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer


Genetic: fluorescence in situ hybridization|Genetic: polymerase chain

reaction|Genetic: protein expression analysis|Other:


biomarker analysis|Other: mass spectrometry

University of Michigan Cancer Center|National Cancer Institute

(NCI)

4350 9-May-09 16-May-09 Jul-07

286 NCT00902733

Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer

Recruiting

Other: medical chart review|Other: questionnaire administration|Procedure: fatigue assessment and management|Procedure:


assessment

Beckman Research Institute|National Cancer Institute

(NCI)

125Primary Purpose: Health

Services Research14-May-09 Jul-08 23-Jun-09 Jun-09 Jul-13

251 NCT00904514

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial


Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: mutation analysis|Genetic: polymerase chain reaction|Other: flow

cytometry|Other: immunoenzyme

technique|Other: laboratory biomarker analysis


241 16-May-09 Oct-07 16-May-09 Mar-08

197 NCT00950144

Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer

Recruiting

Other: medical chart review|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: quality-of-

life assessment

Beckman Research Institute|National Cancer Institute

(NCI)

123 30-Jul-09 Dec-08 30-Jul-09 Jul-09 Apr-11

270 NCT00974610

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer

Recruiting

Genetic: protein analysis|Genetic: proteomic profiling|Other: laboratory

biomarker analysis

All Ireland Cooperative

Oncology Research Group

300 9-Sep-09 Aug-08 9-Sep-09 Sep-09 Oct-10

47 of 47 4/20/2010, 8:16 PM

pancreatic cancer clinical trials

Documents